Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Sep;98(9):E233-E236.
doi: 10.1002/ajh.27005. Epub 2023 Jun 24.

Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study

Courtney D DiNardo  1 , Stéphane De Botton  2 , Daniel A Pollyea  3 , Richard M Stone  4 , Jessica K Altman  5 , Amir T Fathi  6 , Tharin Limsakun  7 , Min Liang  8 , Sung Choe  7 , Mohammad Hossain  7 , Adriana E Tron  7 , Qian Meng  7 , Stephanie M Kapsalis  7 , Shuchi S Pandya  7 , Eytan M Stein  9
Affiliations
Free article
Clinical Trial

Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study

Courtney D DiNardo et al. Am J Hematol. 2023 Sep.
Free article
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Jin J, Hu C, Yu M, et al. Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis. PLoS ONE. 2014;9(6):e100206.
    1. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17(3):225-234.
    1. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739-744.
    1. Harding JJ, Lowery MA, Shih AH, et al. Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition. Cancer Discov. 2018;8(12):1540-1547.
    1. Konteatis Z, Artin E, Nicolay B, et al. Vorasidenib (AG-881): a first-in-class, brain-penetrant dual inhibitor of mutant IDH1 and 2 for treatment of glioma. ACS Med Chem Lett. 2020;11(2):101-107.

Publication types

Associated data

LinkOut - more resources